The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients

NCT01012570 | Terminated

• 1 other identifier: HUM-07-019
• Study Type: observational
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators will study the effect of Adalimumab on the bone microstructure.

• Trial with medicinal product

Conditions

Crohn's Disease

Interventions

Application of Adalimumab DRUG

Adalimumab will be applied according to manufacture's instruction and official guidelines.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients cohort of the University Hospital Zurich

You may qualify if:

• CDAI \> 220 und \< 450
• Biologika naiv
• CD seit \> 6 Monaten

You may not qualify if:

• other TNF-Blocker
• Steroids \> 40 mg
• Malignoma in der Anamnesis

Sponsors & Collaborators

• Gerhard Rogler: lead

Study Sites (1)

Unknown Facility

Zurich, Switzerland

Location

MeSH Terms

Conditions

Crohn Disease

Condition Hierarchy (Ancestors)

Inflammatory Bowel Diseases; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases

Study Officials

• 01 Studienregister MasterAdmins

  UniversitaetsSpital Zuerich

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Prof.Dr.Dr. gerhard Rogler

Study Record Dates

• First Submitted: November 11, 2009
• First Posted: November 13, 2009
• Study Start: August 1, 2009
• Primary Completion: August 1, 2011
• Last Updated: December 4, 2014

Record last verified: 2014-12

Locations

CH (1)